Impacting Millions and on the Rise
Urgent Need for Therapeutic Progress
Despite these staggering statistics and significant advances in treating some liver diseases such as hepatitis C, little progress has been made to address the life-threatening complications of end-stage liver disease.
New interventions to manage the morbidity and mortality of end-stage liver disease are needed urgently.
In people with end-stage liver disease, the liver’s natural ability to regenerate itself is compromised to the point where the body can no longer create and maintain a sufficient number of hepatocytes needed to conduct vital biosynthetic, metabolic and detoxifying functions. This results in life-threatening disease complications and high morbidity.
While liver transplantation is a viable and curative option, many patients are ineligible. For those who are eligible, the number of patients who could potentially benefit from transplant are far outstripped by the available supply of donor organs.
Translating Biological Insights to Deliver Breakthrough Therapeutics
Deeply understanding and interrogating the biological processes that lead to recurring liver injury, which in turn inhibits the liver’s innate ability to regenerate itself and maintain hepatocyte homeostasis, is a major focus of our work at Ambys.
We are rapidly translating these insights about liver injury to advance breakthrough therapies that can spur liver regeneration and restore function.